Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 17,807 matching trials from the live ClinicalTrials.gov search.

Filters: Chicago, Illinois Clear all

Conditions: Multiple Myeloma
Interventions: bb21217; Biological
Lead sponsor: 2seventy bio; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: HIV Infections, Pregnancy
Interventions: Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate, Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 44
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Conditions: Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Interventions: Entinostat, Placebo, Erlotinib; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 30
States / cities: Tucson, Arizona • Denver, Colorado • Miami, Florida + 26 more

Conditions: Primary IgA Nephropathy
Interventions: Nefecon, Placebo oral capsule; Drug
Lead sponsor: Calliditas Therapeutics AB; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 34
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, low dose total body irradiation, Sirolimus; Drug
Lead sponsor: Robert Nickel; Other
Eligibility: 2 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more

Conditions: Soft Tissue Inflammation
Interventions: Standard Hydrocolloid Dressing, Silver Hydrocolloid Dressing; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Month to 17 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Bevacizumab, Carboplatin, Paclitaxel, Placebo, Trastuzumab; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 373
States / cities: Jonesboro, Arkansas • Castro Valley, California • Emeryville, California + 236 more

Conditions: Haematological Malignancies
Interventions: AZD0466, Voriconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab; Other · Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • Lake Forest, Illinois

Conditions: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions: KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Indacaterol/Glycopyrrolate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 80 Years
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Hypertension
Interventions: Rheos® Baroreflex Hypertension System; Device
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more

Conditions: Healthy, Appetite
Interventions: Control, small, Experimental B, small, Experimental pasta C, small, control, medium, experimental pasta B, medium, experimental pasta C, medium, NL; Other
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more

Conditions: Children Under 13
Interventions: No intervention is being administered.; Other
Lead sponsor: National Opinion Research Center; Other
Eligibility: 18 Years and older
Enrollment: 106,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Interventions: Olaparib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Gilbert, Arizona • Orange, California • Stanford, California + 14 more

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions: D-Cycloserine, Placebo (for D-cycloserine); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Pembrolizumab, Pemetrexed, Carboplatin, Comprehensive Geriatric Assessment, Questionnaire Administration, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 70 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 505
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 318 more

Conditions: Superficial Musculoaponeurotic System (SMAS) Procedure
Interventions: Not listed
Lead sponsor: C. R. Bard; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Ponte Vedra Beach, Florida • Chicago, Illinois

Conditions: Cigarette Smoking, Nicotine Dependence
Interventions: Choose to Change, Enhanced usual care; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Huntington's Disease
Interventions: Pridopidine, Placebo; Drug · Other
Lead sponsor: Prilenia; Industry
Eligibility: 21 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more

Conditions: Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions: Brimonidine 0.15%, Brimonidine 0.075%, Placebo; Drug
Lead sponsor: Sandeep Jain, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Alpha 1-Antitrypsin Deficiency, Genetic Disease
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 6 more

Conditions: Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Interventions: Voro Urologic Scaffold; Device
Lead sponsor: Levee Medical, Inc.; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 15 more

Search by objective public record fields.

Study of bb21217 in Multiple Myeloma

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

Rheos® Pivotal Trial

Pasta Formulations, Portion Sizes and Their Effect on Appetite

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

2024 National Survey of Early Care and Education (NSECE)

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

GalaFlex Mesh in Facelift

Reducing Tobacco Use Disparities Among Low-Income Adults

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Pivotal Study of Voro Urologic Scaffold